The effect of DAPA and other SGLT-2 inhibitors in randomized control trials has shown a disease modifying effect on patients with NAFLD in addition to its blood glucose lowering benefits. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.